Twist Bioscience Q1 FY2023 revenue $54.2M (+29% YoY), net loss narrows

Twist Bioscience Corp

2023-Q1 EPS reported -$0.74 revenue$54,243,000

Revenue $54.2M, up 29% YoY; orders $64.7M, up 30% YoY.
Net loss of $41.8M ($0.74/share) improved from $45.6M ($0.91/share) YoY.
Cash and investments $438.7M; first products shipped from Wilsonville Factory of the Future.
Customer count 2,060 (up from ~1,800); gene shipments ~134,000 (vs ~125,000).
Launched NGS panels for rare disease; Astellas collaboration; biopharma partners at 278 with 95 active programs.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

Twist Bioscience Corp reported first quarter of fiscal 2023 ended December 31, 2022 results: revenue $54.2 million, net income $41.8 million, EPS $0.74 per share.

Period: first quarter of fiscal 2023 ended December 31, 2022
Revenue: $54.2 million
Net income: $41.8 million
EPS: $0.74 per share
Result: reported results

Exact text from the filing

• Revenue: Total revenues for the first quarter of fiscal 2023 were $54.2 million compared to $42.0 million for the same period of fiscal 2022 . • Cost of Revenues: Cost of revenues for the first quarter of fiscal 2023 was $29.4 million compared to $27.1 million for the same period of fiscal 2022 . • Research and Development Expenses: Research and development expenses for the first quarter of fiscal 2023 were $31.2 million compared to $22.6 million for the same period of fiscal 2022 . • Selling, General and Administrative Expenses: Selling, general and administrative expenses for the first quarter of fiscal 2023 were $42.3 million compared to $51.1 million for the same period of fiscal 2022 . • Net Loss: Net loss attributable to common stockholders for the first quarter of fiscal 2023 was $41.8 million, or $0.74 per share, compared to $45.6 million, or $0.91 per share, for the same period of fiscal 2022 .

View on SEC.gov

Browse all earnings releases →

Twist Bioscience Corp filing history →

Source: SEC EDGAR

accession 0001628280-23-002145

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.